🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This #WomenInScience Day we’re spotlighting WeiQi Lin, M.D., Ph.D, our Executive VP of Research & Development, Principal Scientist. Dr. Lin has been instrumental in advancing our #epigenetic regulator program. We’re honored to celebrate her achievements & leadership!

At DURECT, our mission is to revolutionize medicine through the power of #epigenetic modulation to address serious and life-threatening conditions. We are committed to improving patient outcomes through innovative treatments. Learn more about our mission: bit.ly/3WMk0db

Investigators of our completed AHFIRM Phase 2b study on alcohol-associated hepatitis (AH) will present trial data at @AASLDTweets’ Emerging Topics Conference 2025. Learn more here: bit.ly/4gq0PNN

New research continues to show that rates of alcohol-associated #hepatitis (#AH) are increasing rapidly among adolescents and young adults, especially women, highlighting the need for effective interventions. Learn more in this @HCPLIveNews article: bit.ly/4hrr0nA

Our CEO, Jim Brown, DVM, was featured in Citeline Scrip Asks article to discuss therapeutic areas with the greatest advances for 2025. Read to see his insights on #epigenetics' potential to revolutionize therapies across a variety of diseases. More here: bit.ly/3XbMvRm

Our CMO, Norman Sussman, M.D, had a productive time at the recent @AASLDFoundations’ Emerging Topics Conference 2025, discussing the #AHFIRM trial data on alcohol-associated #hepatitis (#AH) with key hepatologists and alcohol-related liver disease experts.

Our CMO, Norman Sussman, MD, will participate in the Chief Medical Officer 360° Summit (#CMO360), hosted by @ConferenceSummit, April 7-8 in Boston to discuss “Enhanced strategic FDA collaboration” and network with CMOs across company stages. Learn more: bit.ly/3DuUjHg

Save the date for our fourth quarter and full year 2024 financial results & business update conference call on March 26th. For more information and to access the live webcast, visit: bit.ly/3DU4B3Q

Today we reported our fourth quarter and full year 2024 financial results and provided a corporate update. For more information and to access the webcast replay, visit: bit.ly/3Y6EAVJ

In a recent @XTalks article, our President & CEO, Dr. Jim Brown, joined Vera Kovacevic to highlight the potential for #EpigeneticModulation as a new therapeutic approach to treat alcohol-associated #hepatitis (#AH). Read the article to learn more: bit.ly/4jkb3QN

#ICYMI, our CMO, Norman Sussman, M.D, participated in a panel at the Chief Medical Officer 360º Summit (#CMO360) to discuss the importance of strategic collaborations with the FDA. Thank you for a great meeting and the opportunity to connect with industry peers!

This #AlcoholAwarenessMonth we’re recognizing the impact of alcohol-associated liver diseases and the urgent need for better treatment options. We’re advancing a therapy to treat alcohol-associated #hepatitis (#AH) and improve patient outcomes. Learn more: bit.ly/42Q0Upq

A previous エアリオ@モナリザ福岡2日目 article featuring Mitchell Shiffman, M.D., highlights the need for new treatments in alcohol-associated hepatitis (#AH). This #AlcoholAwarenessMonth, learn about this condition & potential of our therapy to make an impact. Read more: bit.ly/4cbq6Jo

With a mortality rate of approximately 30% at 90 days, there are no approved therapies for alcohol-associated #hepatitis (#AH). At DURECT, we are developing what could be the first treatment for AH. Learn more in our latest AASLD poster: bit.ly/4gy5Bsf

Happy to share our publication in Hepatology Communications, which provides methods to address the confounding effect of early liver transplantation in clinical trials in patients with alcohol-associated hepatitis. Read here: bit.ly/3Se1I1f

In this Clinical Trial Vanguard article our CEO Jim Brown, DVM, discussed our lead candidate’s promising clinical trial results to potentially transform the treatment of alcohol-associated #hepatitis (#AH). Read here to learn more: bit.ly/3SdHC7g

Epigenetic modulators play a crucial role in regulating gene expression. At DURECT, we’re harnessing the potential of #epigenetic therapies to address the challenges of dysregulated epigenomes to deliver treatments for patients in need. Learn more: bit.ly/4ckMIXW

Today, we reported our first quarter 2025 financial results and provided a corporate update. Check out our press release to learn more: bit.ly/3GT2tu9

Today is #ClinicalTrialsDay and we’re happy to see our CMO, Norman Sussman, M.D., featured in this Clinical Leader article, discussing key insights that informed the design of our upcoming Phase 3 trial in alcohol-associated hepatitis (#AH). Read here: bit.ly/4kb61qI

Pleased to have been selected as one of the AASLD 2024 Liver Meeting abstract top picks by Ashwani Singal, MD, MS, in a Gastroenterology & Endoscopy News article. Read more as he discusses results of our Phase 2b #ClinicalTrial in alcohol-associated #hepatitis (#AH): bit.ly/4mGUv7Q